KMD Brands Ltd (ASX: KMD) shares are ending the week deep in the red.

In morning trade, the ASX All Ords share is down 10% to a 52-week low of 35 cents.

Why is this ASX All Ords share crashing?

Investors have been hitting the sell button today after the Kathmandu owner released another disappointing trading update.

As a reminder, during the first half of FY 2024, group sales were down 14.5% compared to the same period last year.

According to today’s release, the company’s sales in the second half have improved since the end of the first half. However, they are still down compared to the prior corresponding period.

Investors appear particularly disappointed with the performance of the Kathmandu business. Management notes that it has experienced a slower than expected start to the key winter promotional period.

The first three weeks of the winter sale are 11.5% below last year and lower than the improving second half trend. This reflects significant weakness in New Zealand, with Australian sales down in line with current sales trends. They have also improved each week as it progresses further into the winter season.

One positive is that Rip Curl has started its peak summer trade in the Northern Hemisphere. Management notes that direct-to-consumer sales for the USA and Europe for the start of summer are showing positive single digit growth above last year and peak weeks are still to come.

However, Rip Curl and Oboz wholesale customers continue to reduce their inventory in response to the challenging consumer environment.

The sum of the above, is that second half group sales were down 8.4% through to the end of May. This reflects a 5.9% decline in Rip Curl sales, an 8.4% drop in Kathmandu sales, and a 21.8% fall in Oboz sales.

In light of this and based on the most recent sales trends across all brands, the company now expects underlying EBITDA to be approximately NZ$50 million for the full year. This will be down over 50% from NZ$105.9 million in FY 2023.

The ASX All Ords share’s managing director, Michael Daly, said:

With six weeks of peak trade still to come, we remain focused on optimising our Kathmandu winter and Rip Curl Northern Hemisphere summer results in a challenging consumer environment. We are seeing a prolonged impact of cost-of-living pressures on consumer sentiment globally but particularly in New Zealand, and we continue to respond tactically to competitive market dynamics. Alongside immediate trading priorities, our focus remains on tightly controlling operating costs, moderating working capital, and maximising cash flows.

The post Why is this ASX All Ords share crashing deep into the red on Friday? appeared first on The Motley Fool Australia.

More reading

• Analysts say these strong ASX 200 blue chip shares are top buys today
• Guzman y Gomez share price implodes 10% on ASX trading day 2
• Want to buy Nvidia but don’t have a US share account? Buy these ETFs instead
• Botanix shares jump on FDA approval and $70m capital raising
• Pilbara Minerals shares drop on major P2000 lithium expansion news

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

It’s the era of Nvidia Corp (NASDAQ: NVDA).

This week, the US tech giant has continued to dominate financial headlines. Yesterday, everyone was talking about how it became the largest company in the US stock market. This morning, the buzz is about its 3% overnight drop.

Nvidia shares have delivered impressive returns for its shareholders, surging 171% since January 2024, including a breathtaking 38% gain in the past month.

However, not everyone has direct access to US shares or feels comfortable navigating the complexities of investing in foreign markets, let alone dealing with the hassle of creating an international trading account.

This brings up an intriguing alternative: investing in exchange-traded funds (ETFs) that include Nvidia in their portfolios.

Let’s first hear what experts say about Nvidia’s future. Then explore ASX ETFs that offer the best exposure to the company.

What experts say about Nvidia shares

Analysts remain optimistic about Nvidia’s future. The company enjoys its leadership in graphics processing units (GPUs) and its expanding presence in artificial intelligence (AI).

The company’s recent advancements in AI technology have positioned it at the forefront of the industry, attracting significant attention and investment. Nvidia boasts over 80% market share in the important AI market keeping competitors at bay, as my colleague Keithen highlighted.

Despite lofty valuations, many predict the company’s growth to continue as it leverages its cutting-edge technology to explore new markets and opportunities.

Betashares Nasdaq 100 ETF (ASX: NDQ)

One ETF that stands out for providing excellent exposure to Nvidia is the BetaShares NASDAQ 100 ETF. This ETF tracks the performance of the NASDAQ 100 Index, which includes 100 of the largest non-financial companies listed on the NASDAQ stock market.

At present, Nvidia represents 8.7% of this ETF, making the NDQ ETF a great option for those looking to invest in Nvidia indirectly.

By investing in NDQ, you’re not only gaining exposure to Nvidia but also to other leading tech giants like Apple, Amazon, and Microsoft. This diversification helps mitigate the risks associated with investing in a single stock.

The NDQ ETF charges a management fee of 0.48%.

Other ASX ETFs with Nvidia shares

Other ASX ETFs that own Nvidia shares are Global X Semiconductor ETF (ASX: SEMI) and Betashares Metaverse ETF (ASX: MTAV), as my colleague James highlighted.

• Global X Semiconductor ETF has 13% of its net assets invested in Nvidia with a management fee of 0.45%
• Betashares Metaverse ETF has 8% of its net assets invested in Nvidia with a management fee of 0.69%

The Global X Semiconductor ETF has the highest exposure to Nvidia, with the rest invested in the eco-system of the AI industry. The constituents include semiconductor equipment makers like Taiwan Semiconductor Manufacturing and ASML Holding.

These are all market leaders in their respective fields, located in Taiwan and the Netherlands. This ETF might be more suitable for those seeking broader global exposure in the industry.

This ETF is up 68% over the past year.

The Betashares Metaverse ETF has a similar exposure to Nvidia with a higher management fee. This ETF is up 37% over the past year.

The post Want to buy Nvidia but don’t have a US share account? Buy these ETFs instead appeared first on The Motley Fool Australia.

More reading

• Thinking about buying Nvidia stock? Here’s why you might already own it
• Nvidia investors just got some bullish news
• Is Nvidia stock going to $200 in the wake of its 10-for-1 stock split?
• Can anyone topple Nvidia as the king of artificial intelligence investments?
• We see patterns everywhere. That’s not always helpful.

John Mackey, former CEO of Whole Foods Market, an Amazon subsidiary, is a member of The Motley Fool’s board of directors. Motley Fool contributor Kate Lee has positions in Microsoft and Nvidia. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Amazon, Apple, BetaShares Nasdaq 100 ETF, Microsoft, and Nvidia. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool Australia has positions in and has recommended BetaShares Nasdaq 100 ETF. The Motley Fool Australia has recommended Amazon, Apple, Microsoft, and Nvidia. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Botanix Pharmaceuticals Ltd (ASX: BOT) shares are ending the week on a positive note.

In morning trade, the clinical dermatology company’s shares are up 9% to a 52-week high of 36.5 cents.

Why are Botanix Pharmaceuticals shares rising?

Investors have been buying the company’s shares today in response to an announcement relating to its Sofdra product.

Yesterday, Botanix revealed that the US Food and Drug Administration (FDA) has approved Sofdra as a prescription medicine used to treat primary axillary hyperhidrosis (excessive underarm sweating) in adults and children 9 years and older.

This makes it the first and only new chemical entity approved by the FDA to treat primary axillary hyperhidrosis and presents a novel safe and effective solution for patients who have lacked treatment options for this socially challenging medical condition.

Botanix notes that there are approximately 10 million people in the United States with primary axillary hyperhidrosis, with few effective treatments available for patients. This gives it a large market opportunity to grow into.

Speaking of which, the company plans to launch its patient experience program in the third quarter of 2024. After which, it is anticipating its first revenue from Sofdra early in the fourth quarter of the year.

Botanix CEO, Dr Howie McKibbon, commented:

We are pleased to share this accomplishment with our dedicated Botanix team and dermatologist partners, patients who participated in the clinical studies and our shareholders who made this approval possible. This is a transformative event for Botanix as we transition from a development stage to a revenue generating dermatology company.

Capital raising

Following the FDA approval, Botanix decided to immediately launch a capital raising, which is now complete.

Management revealed that it has received firm commitments from a significant number of new leading Australian and international institutional investors at a 10.4% discount of $0.30 per new Botanix share. This has raised $70 million in gross proceeds.

The proceeds from the placement will be applied towards funding the launch of Sofdra in the United States. This includes funding its sales force and marketing infrastructure, as well as digital marketing costs and the telemedicine platform, manufacturing costs, as well as new quality assurance, pharmacovigilance and support services.

Botanix’s executive chairman, Vince Ippolito, commented:

We are extremely pleased to announce this significant Placement, following on from the successful approval of Sofdra by the FDA yesterday. We are grateful to our loyal base of shareholders for supporting us through the approval of Sofdra and we welcome our new institutional investors, as we enter this exciting commercial phase.

Botanix shares are up over 200% since this time last year.

The post Botanix shares jump on FDA approval and $70m capital raising appeared first on The Motley Fool Australia.

More reading

• Botanix Pharmaceuticals share price on watch amid FDA news and ‘transformative event’
• Guess which high-flying ASX All Ords stock was just halted ahead of a key FDA decision
• Why Bapcor, Botanix, Judo Capital, and Woodside shares are rising today
• Which ASX biotech shares are pioneering the future of medicine?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Pilbara Minerals Ltd (ASX: PLS) shares are falling on Friday morning.

At the time of writing, the lithium miner’s shares are down 2% to $3.13.

Why are Pilbara Minerals shares falling?

Investors have been selling the lithium giant’s shares following the release of the pre-feasibility study (PFS) for the expansion of production at the Pilgangoora Operation.

According to the release, the PFS determined that production capacity at Pilgangoora Operation could be expanded to more than 2 million tonnes per annum (Mtpa).

As a comparison, for the first three quarters of FY 2024, Pilbara Minerals has delivered production of 499.2 kt.

Management notes that the expansion, which will be named the P2000 Project, is expected to result in the first ten years of annual production averaging ~1.9Mtpa. After which, production of more than 2Mtpa is expected over the first six years after the ramp up.

It believes that P2000 would further extend Pilbara Minerals’ position as the largest pure-play lithium producer globally.

However, the timing of the P2000 Project will depend on the successful outcome of the next level of feasibility study, project approvals, and the market outlook at the time of the financial investment decision (FID).

What are the costs?

The company notes that P2000 would require construction of a new whole of ore flotation plant at Pilgangoora. This would come with an estimated capital expenditure of $1.2 billion (-20/+30% accuracy).

The new plant would complement existing processing flowsheets in use at the Pilgangoora Operation.

Management believes it would be well worth the cost. It estimates that the expansion will create significant shareholder value with a P2000 incremental net present value (NPV) of $2.6 billion and incremental internal rate of return (IRR) of 55%.

This is based on the assumption of a long term spodumene 6% price of US$1,500 per tonne.

Though, it is worth noting that Goldman Sachs estimates that the long term spodumene 6% price will be just US$1,150. At that level, based on its sensitivity chart, the NPV drops closer to $1 billion.

So, investors may need to decide whether the assumptions used for this expansion are too ambitious or not.

Pilbara Minerals has now commenced a feasibility study in relation to P2000. Outcomes are expected in the December quarter of calendar year 2025. A potential FID will follow this.

‘A strong value accretive project’

Pilbara Minerals managing director and CEO, Dale Henderson, was pleased with the PFS. He said:

The PFS demonstrates a strong value accretive project with an incremental NPV of $2.6B through this potential future expansion to the operation at Pilgangoora. This study follows the 35% reserve upgrade to 214Mt announced in August last year.

The growth of the reserve, and the optionality to incrementally expand production, further reinforces Pilgangoora’s position as a Tier 1 asset of global significance.

This expansion is expected to provide an average 1.9Mtpa production for the first 10 years and more than 2Mtpa over the first six years after ramp up. The scale benefits of this expansion will further build on Pilbara Minerals’ position as one of the major leading lithium suppliers globally.

Pilbara Minerals shares are down 37% over the last 12 months.

The post Pilbara Minerals shares drop on major P2000 lithium expansion news appeared first on The Motley Fool Australia.

More reading

• Buy these ASX dividend shares for 5% to 6% yields
• 5 things to watch on the ASX 200 on Friday
• 5 things to watch on the ASX 200 on Thursday
• Here are the top 10 ASX 200 shares today
• Here’s the earnings forecast out to 2027 for Pilbara Minerals shares

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The team at Morgans has been busy picking out its best ASX share ideas for June.

The first two ASX stocks we looked at can be found here. Read on for three more picks:

Clearview Wealth Ltd (ASX: CVW)

Morgans is positive on this financial services company and sees it as an ASX stock to buy in June.

The broker likes the company due to its large opportunity in the retail life insurance market, its business transformation program, and undemanding valuation. It commented:

CVW is a challenger brand in the Australian retail life insurance market (market size = ~A$10bn of in-force premiums). CVW sees its key points of differentiation as its: 1) reliable/trusted brand; 2) operational excellence (in product development, underwriting and claims management); and 3) diversified distributing network. CVW’s significant multiyear Business Transformation Program has, in our view, shown clear signs of driving improved growth and profitability in recent years. We expect further benefits to flow from this program in the near term, and we see CVW’s FY26 key business targets as achievable. With a robust balance sheet, and with our expectations for ~21% EPS CAGR over the next three years, we see CVW’s current ~11x FY25F PE multiple as undemanding.

Morgans has an add rating and 78 cents price target on its shares.

GUD Holdings Limited (ASX: GUD)

Another ASX stock that Morgans is bullish on is GUD. It is a diversified products company with a focus on the auto market.

The broker thinks GUD is a high quality company and sees its investment case as compelling. It explains:

GUD is a high-quality business with an entrenched market position in its core operations and deep growth opportunities in new markets. We view GUD’s investment case as compelling, a robust earnings base of predominantly non-discretionary products, structural industry tailwinds supporting organic growth and ongoing accretive M&A optionality. We view the ~12x multiple as undemanding given the resilient earnings and long-duration growth outlook for the business ahead.

Its analysts have an add rating and $13.71 price target on its shares.

Stanmore Resources Ltd (ASX: SMR)

A final ASX stock that could be a buy according to Morgans is coal miner Stanmore Resources.

Its analysts believe that coal prices could trade significantly higher than expectations in the future and expect Stanmore Resources to benefit. They said:

SMR’s assets offer long-life cashflow leverage at solid margins to the resilient outlook for steelmaking coal prices. We’re strong believers that physical coal markets will see future cycles of “super-pricing” well above consensus expectations, supporting further periods of elevated cash flows and shareholder returns. We like SMR’s ability to pay sustainable dividends and its inventory of organic growth options into the medium term, with meaningful synergies, and which look under-recognised by the market. We see SMR as the default ASX-listed producer for pure met coal exposure. We maintain an Add and see compelling value with SMR trading at less than 0.8x P/NPV.

Morgans has an add rating and $4.20 price target on its shares.

The post Morgans names more of the best ASX stocks to buy in June appeared first on The Motley Fool Australia.

More reading

• Bell Potter says these ASX 200 shares are strong buys with 20%+ upside
• Here are the top 10 ASX 200 shares today
• Analysts name 2 ASX dividend shares to buy now

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

By now, you’ve probably heard all about NVIDIA Corporation (NASDAQ: NVDA) stock and its prowess and future potential in artificial intelligence (AI). You’ve probably also caught wind of its mind-boggling stock price gains that its lucky investors have been enjoying.

To put some numbers on it, the Nvidia share price has gained an eye-watering 181.46% over 2024 to date alone (going off the stock price as of Wednesday night’s close).

Over the past 12 months, investors have netted a rise of 209.47%, which stretches to a monstrous 3,477% over the past five years.

These gains have even been enough to push Nvidia to claim the title of ‘world’s largest company’. Yes, just this week, Nvidia surpassed Microsoft to take that crown. At the time of writing, it commanded a jaw-dropping market capitalisation of US$3.34 trillion. For some context, that’s more than the size of the entire Australian economy. Nearly twice over, in fact.

So this is a stock that has no doubt changed the lives of more than a few investors. If you don’t already own shares and you’re a sucker for punishment, check out the graph below for a graphical representation of this company’s astonishing ascendancy:

With such a dramatic and usual rocketship-like trajectory, Nvidia stock is bound to give most of us at least some feelings of missing out. That’s if you don’t already own shares of course.

However, before you rush out and buy Nvidia, there’s something important to consider. Chances are you’re probably already an owner of Nvidia shares. In fact, most Australians can probably claim they own a small piece of this company, whether they know it or not.

How?

Why most Australians own a slice of Nvidia stock… even if they don’t know it

Well, Nvidia’s rise has had some auxiliary consequences. For one, it has pushed the allocation that many index funds and exchange-traded funds (ETFs) have to Nvidia stock. Because these funds give weighting to different companies based on market capitalisation, Nvidia’s rise means that any index fund that already included Nvidia needs to raise its allocation to this stock proportionately

To illustrate, buying a popular US-based ETF like the iShares S&P 500 ETF (ASX: IVV) today will mean that out of every dollar invested, 7.3 cents will go into Nvidia shares.

So any ASX investor who owns any ETF or index fund that holds international or US shares probably has exposure to Nvidia stock right now.

But so would most Australians with a superannuation fund. That is to say, the vast majority of the adult population in this country.

Most Australian workers have their super invested in what’s known as a ‘balanced’ fund. It’s called this because the fund aims to invest in a variety of asset classes in order to balance the maximisation of your financial returns with reducing fund volatility. These asset classes usually include ASX shares, infrastructure, cash, bonds, property, and international shares.

Chances are one of the international shares in your super fund’s portfolio will be Nvidia. Given that Nvidia has been one of the top ten shares in the US market by size for a few years now, it is highly likely that your super fund has a position in the company.

If your super fund has grown in value over the past 12 months, you can probably partly thank Nvidia for that too. This scenario just goes to show how beneficial superannuation can be for everyone in the country today.

Foolish takeaway

Watching a stock like Nvidia explode in value from the sidelines might be hard. But we should all take comfort from the fact that almost everyone is benefitting from its rise, even in an indirect and relatively modest manner.

The post Thinking about buying Nvidia stock? Here’s why you might already own it appeared first on The Motley Fool Australia.

More reading

• Nvidia investors just got some bullish news
• Is Nvidia stock going to $200 in the wake of its 10-for-1 stock split?
• Can anyone topple Nvidia as the king of artificial intelligence investments?
• We see patterns everywhere. That’s not always helpful.
• Nvidia shares reach world’s most valuable milestone. Where to now?

Motley Fool contributor Sebastian Bowen has positions in Microsoft. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Microsoft, Nvidia, and iShares S&P 500 ETF. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended the following options: long January 2026 $395 calls on Microsoft and short January 2026 $405 calls on Microsoft. The Motley Fool Australia has recommended Microsoft, Nvidia, and iShares S&P 500 ETF. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Fancy grabbing a 917% one-year return from your ASX healthcare stock investment?

Me too!

The stock in question is clinical stage drug discovery and development company Dimerix Ltd (ASX: DXB)

As you can likely guess by the phenomenal share price growth, shown in the chart below, a lot’s been going right with the company’s drug development and discoveries.

Yep, just one year ago, you could have bought the ASX healthcare stock for 6.0 cents a share.

At market close on Thursday, shares finished trading up 9.91%, swapping hands for 61 cents apiece.

That’s enough to turn a $5,000 investment into a whopping $50,833 in just 12 months.

Take that inflation!

Here’s why investors have been sending the stock through the roof.

How has the ASX healthcare stock rocketed 858% in a year?

As mentioned up top, Dimerix has released numerous promising updates on its operations and product line over the year.

One of the biggest share price moving pieces of news was released on 5 October.

Investors sent the ASX healthcare stock rocketing 154.1% higher in a single day after the company, together with Advanz Pharma, reported it had entered into an exclusive license agreement for the European Economic Area, the UK, Switzerland, Canada, Australia, and New Zealand for the commercialisation of its phase 3 drug candidate DMX-200.

DMX-200 is intended to treat focal segmental glomerulosclerosis kidney disease.

Also likely boosting investor sentiment in the ASX healthcare stock was the fact that Dimerix retained all rights to commercialise DMX-200 outside of these territories.

“We are excited to announce this partnership with Dimerix, which is fully in line with our strategy to be a partner of choice for the commercialisation of specialty, hospital, and rare disease medicines in Europe, Canada, and Australia,” Advanz Pharma CEO Steffen Wagner said on the day.

The good times kept coming

As mentioned, Dimerix shares kept on gaining as the company released a series of other positive announcements over the following months.

Most recently, on 27 May, the ASX healthcare stock closed up 25.0% after reporting that Taiba Middle East had acquired exclusive rights to register and commercialise DMX-200 in the United Arab Emirates, Saudi Arabia, Oman, Kuwait, Qatar, Bahrain and Iraq.

Atop the deal inked with Advanz Pharma, the two license deals provide almost $11.5 million in upfront payments to the ASX healthcare stock along with some $340 million in potential milestone payments.

“We are thrilled to partner with Dimerix in launching DMX-200 in the Middle East pending FDA approval,” Taiba CEO Saif Al Hasani said.

The post If you invested $5,000 in this ASX healthcare stock a year ago, you’d have $50,833 now! appeared first on The Motley Fool Australia.

More reading

• 2 ASX biotech shares that could be the next Telix Pharmaceuticals

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Treasury Wine Estates Ltd (ASX: TWE) shares could be great value at current levels.

That’s the view of analysts at Goldman Sachs, which have just increased their valuation of the ASX 100 stock.

This follows the release of the wine giant’s Penfolds update on Thursday.

What is the broker saying about this ASX 100 stock?

Goldman was pleased with the company’s update. And while it acknowledges that its Penfolds guidance for next year was a touch short of expectations, it thinks investors should look beyond this and focus on its strong outlook for FY 2026 and FY 2027. Its analysts commented:

TWE announced an update on its Penfolds outlook and strategy this morning together with Sales/EBITS/EBITS margin guidance for FY24-27. Whilst stock reaction was muted given FY25 Penfolds EBITS guide ~3.5% below Visible Alpha consensus, we believe that the ~15% CAGR in FY26/27 EBITS excluding any price increase is strong and demonstrates management confidence in execution despite the highly volatile consumer environment.

The broker also highlights the high quality of the ASX 100 stock’s earnings. It adds:

We believe that the building blocks of the EBITS growth to FY27 is balanced and of high quality, including FY25 ~+6% weighted average price in Bins & Icons (GSe ~3% across total Penfolds portfolio), FY26/27e ~15% volume and mix; with longer-term EBITS margin target at 45%.

Big returns expected

According to the note, the broker has reiterated its buy rating and lifted its price target on its shares to $15.20 (from $13.40).

Based on the current Treasury Wine share price of $12.43, this implies potential upside of 22% for investors over the next 12 months.

In addition, Goldman is forecasting dividend yields of 2.8% in FY 2024 and then 3.5% in FY 2025 from the ASX 100 stock. This stretches the total 12-month potential return to approximately 25%.

Commenting on its earnings forecasts and valuation, the broker commented:

Accordingly, we revise our group FY25/26 NSR and EBITS +1.0%/+2.4% and +0.9%/+6.7% respectively, and now factor 11%/15% Penfolds EBITS growth in FY25/26 vs mgmt guidance of low double-digit and 15%. We also roll-forward our SOTP/DCF valuation from FY25 to FY26 and introduce FY27 estimates. We revise our 12m forward TP to A$15.2/sh (vs previous A$13.4/sh). TWE is trading on a FY25 forward P/E of 20x vs FY24-27 EPS growth of 14%, implying 1.4 PEG (attractive vs the rest of our global growth Consumer coverage). Reiterate Buy.

Overall, this could make Treasury Wine shares worth considering if you’re looking for new portfolio additions.

The post Guess which ASX 100 stock has ‘high quality’ earnings and could rise 22% appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Friday
• Treasury Wine share price tumbles on Penfolds China update
• Here are the top 10 ASX 200 shares today
• Here’s why the Treasury Wine share price is beating the ASX 200 today
• 5 top ASX growth shares to buy in June

Motley Fool contributor James Mickleboro has positions in Treasury Wine Estates. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Are you hunting for ASX dividend stocks to buy? If you are, it could be worth looking at the ones in this article.

That’s because they have all recently been named as buys and tipped to offer attractive dividend yields. Here’s what you need to know about them:

Centuria Industrial REIT (ASX: CIP)

The first ASX 200 dividend stock that could be a buy according to analysts is Centuria Industrial.

It is Australia’s largest domestic pure play industrial property investment vehicle. Centuria Industrial owns a portfolio of 88 high-quality, fit-for-purpose industrial assets worth a collective $3.8 billion. Management notes that these assets are situated in key in-fill locations and close to key infrastructure.

UBS is positive on the company and currently has a buy rating and $3.71 price target on its shares.

As for dividends, the broker is expecting Centuria Industrial to pay dividends per share of 16 cents in both FY 2024 and FY 2025. Based on the current Centuria Industrial share price of $3.10, this will mean dividend yields of 5.15% for income investors across both years.

Coles Group Ltd (ASX: COL)

Another ASX 200 dividend stock that could be a great option for income investors is supermarket giant Coles.

That’s the view of analysts at Morgans, which believe that company is well-placed to reward shareholders with attractive dividend yields in the coming years.

It is forecasting Coles to pay fully franked dividends of 66 cents per share in FY 2024 and 69 cents per share in FY 2025. Based on the current Coles share price of $17.17, this implies yields of approximately 3.85% and 4%, respectively.

Morgans currently has an add rating and $18.95 price target on its shares.

South32 Ltd (ASX: S32)

A third ASX 200 dividend stock that could be a buy for patient income investors is mining giant South32.

Although the miner may not be in a position to pay a big dividend this year, things could soon change.

That’s because the team at Goldman Sachs believes that its dividend could increase significantly. This is thanks to the favourable outlook for copper, aluminium, zinc, and met coal prices.

Goldman is forecasting fully franked dividends per share of 4 US cents in FY 2024, 10 US cents in FY 2025, and then 16 US cents in FY 2026. Based on its latest share price of $3.70 and current exchange rates, this will mean yields of 1.6%, 4%, and 6.5%, respectively.

The broker currently has a buy rating and $4.00 price target on South32’s shares.

The post Mining, supermarkets, and property: 3 ASX 200 dividend stocks to buy appeared first on The Motley Fool Australia.

More reading

• 9 popular ASX REITs with ex-dividend dates next week
• Coles shares flat as Choice report says competitor Aldi cheapest
• Are ASX REITs a good investment right now?
• 3 of the best ASX 200 blue chip shares to buy now
• 3 reasons to be positive on ASX 200 shares in FY25 (and 3 to be wary)

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Goldman Sachs Group. The Motley Fool Australia has positions in and has recommended Coles Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.